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Calcium influx is the final pathway of death in hypoxia.
Numerous randomized clinical trials have been
conducted to assess the effect of calcium channel
blockade for neuroprotection in acute ischaemic stroke
but the majority of them failed to show any benefit.
What is the study under consideration? 
"Ginsenoside-RD improves the outcome of acute
ischaemic stroke", is the randomized double blind
placebo-controlled multicenter trial by Liu et al which
described that Ginseniside-RD, a receptor operated
calcium channel antagonist that improved the functional
outcome in patients with acute ischaemic stroke. 
What was the study design? 
This study enrolled patients aged 18-75 years with the
clinical diagnosis of primary ischaemic stroke, who
presented within 72 hours after onset of the
symptoms. They selected the patients with NIHSS
score of 5-22 (moderate strokes). These patients
received the daily infusion of Ginesinoside-RD or
placebo for 14 days. 
What was the outcome? 
They noticed that Ginesinoside- RD markedly improved
the mRs at 3 months with no short term improvement of
neurological function in non-lacunar stroke. For lacunar
stroke they reported that the improvement of short term
neurological function determined by NIHSS score was
present on day 15. 
What were the conclusions? 
They concluded that Ginesinoside-RD has its early effect
on free radical scavenging pathway by protecting the
mitochondria, restoring the energy and inhibiting the
apoptosis. It has late anti-inflammatory effect as well. This
agent does not cause hypotension.
Why is this study important?
Of the 15 million stroke deaths, two thirds occur in
developing countries. We have only one option for the
reduction of disability from acute stroke in the form of tissue
plasminogen activator which has a very narrow window
period of 3 to 4.5 hours with risk of bleed as well. We need
safer agents with longer therapeutic windows to treat more
patients. Ginsenoside-RD has a long window period of 72
hours which will enable more patients to fall in this window.
It is interesting that this agent is showing neuroprotective
effects, since most trials have hitherto failed to do so. It does
raise the hope for neuroprotection in stroke.
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